Dynamos

Dyne Therapeutics Announces CEO Transition

Retrieved on: 
Monday, March 25, 2024
Arizona State University, California State University, Cell biology, Research, University, DM1, Dynamos, Biology, MBA, Biogen, Bioverativ, Therapy, DYN, DMD, Management

WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the appointment of John Cox as president, chief executive officer (CEO) and a member of the Board of Directors, effective immediately. He succeeds Joshua Brumm, who has chosen to step down from these roles to pursue a career in healthcare investing. Mr. Brumm will serve as an advisor to Dyne to help ensure a seamless transition.

Key Points: 
  • - John Cox, Industry Leader with Global Experience in Rare Disease Commercialization, Joins Dyne as President and CEO -
    WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc .
  • Mr. Brumm will serve as an advisor to Dyne to help ensure a seamless transition.
  • Having worked extensively in rare diseases, I appreciate the meaningful impact that novel therapeutics can have on a patient community,” said Mr. Cox.
  • Most recently, he served as CEO of Repertoire Immune Medicines and its predecessor from 2019 until 2022.

Imagine What It's Like to Talk to Astronauts While They Are Orbiting the Earth. Indianapolis Children Got To Do Just That

Retrieved on: 
Wednesday, August 31, 2022
Orbit, Mathematics, CEO, Lindgren, International Space Station programme, Work, Research, Emergency medicine, Science, technology, engineering, and mathematics, The Children's Museum of Indianapolis, NASA TV, SpaceX Crew-4, Radio, SpaceX Crew-1, Museum, International Space Station, Humanities, Television, NASA, Children, Astronaut, Learning, Heritage, Vegetable, Water, Student, Old National Bank, Altitude, Human, Crew Dragon Demo-2, Immune system, ISS, Mobile, Cherokee heritage groups, Dynamos, The Children's Museum, Lettuce, Ice, Family, Toy, Communications satellite, Tutoring, Immunosenescence, Engineering, Science, Technology, Facebook

Ky (Anderson) followed up with, "How does water behave in space?" Everyone giggled as Lindgren gave a demonstration and said, "Water is absolutely amazing. We take advantage of orbiting laboratory to examine how fluids move and work in space. So here's a little example -- This is how we drink juice or water depending on if it's a hot or cold drink. And you can see if I push a little bit of water out here… it assumes the shape of a sphere. It's shaking a little bit and I'll release it from the straw."

Key Points: 
  • INDIANAPOLIS, Aug. 31, 2022 /PRNewswire-PRWeb/ -- Indianapolis area students got to 'space-out' with an actual astronaut who was orbiting Earth on the International Space Station (ISS) today.
  • Lindgren answered, "Back 25 years ago the only way astronauts could talk with their families back on the ground was with amateur radio with a ham radio.
  • We take advantage of orbiting laboratory to examine how fluids move and work in space.
  • And you can see if I push a little bit of water out here it assumes the shape of a sphere.

Dyne Therapeutics Announces Submission of IND Application to Initiate Clinical Trial of DYNE-251 for Duchenne Muscular Dystrophy

Retrieved on: 
Thursday, December 2, 2021
Patient, Dystrophin, Myopathy, Heart, Security (finance), Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, Degenerative disease, DM1, Disease, Time, Private Securities Litigation Reform Act, Investigational New Drug, Form 10-Q, FORCE, Muscle, Dynamos, Clinical trial, IND, SEC, Securities and Exchange Commission (Philippines), Therapy, Male, COVID-19, MAD, Exon, DYN, Nasdaq, Twitter, Western blot, GLOBE, FSHD, Terminology, Â, Diaphragm, FDA, Mortality, Duchenne muscular dystrophy, LinkedIn, Facioscapulohumeral muscular dystrophy, PMO, Transferrin, Duchenne, DMD, Food, Pharmaceutical industry

WALTHAM, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a clinical trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) amenable to skipping exon 51.

Key Points: 
  • Planned endpoints include safety and tolerability, PK/PD, dystrophin expression as measured by Western Blot, and measures of muscle function.
  • In addition to DYNE-251, Dyne is building a DMD franchise with programs for patients with mutations amenable to skipping exons 53, 45 and 44.
  • DYNE-251 is Dynes therapeutic candidate being developed for people living with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping.
  • However, while Dyne may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.